New Orleans, LA, United States
New Orleans, LA, United States

Time filter

Source Type

SALT LAKE CITY, May 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new data demonstrating the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer. The data are being presented tomorrow at the American Urological Association (AUA) 2017 Annual Meeting in Boston, Mass. This study was conducted in collaboration with Stephen Bardot, M.D., and colleagues at Ochsner Clinic in New Orleans, Louisiana.  A total of 767 men with localized prostate cancer were evaluated using the Prolaris test plus CAPRA (i.e., clinical features) to predict the risk of metastatic disease up to 10 years following diagnosis.  Approximately 40 percent of the patients in the study were African Americans (AA).  Among all 767 patients 39 men, or 5.1 percent, developed metastases and among the 646 men who received definitive therapy (e.g., surgery, radiation, radiation and hormones) 28 men, or 4.3 percent, developed metastatic disease. The results showed that the Prolaris test was a significant predictor of metastatic disease with a nearly 3-fold increased risk for each one-unit increase on the Prolaris test score (Hazard Ratio per unit score = 2.76; P = 2.8x10-11).  Importantly, there was no difference in predictive performance between races (p=0.20) or treatment groups (p=0.09).  When combined with CAPRA the Prolaris test was highly predictive of metastatic disease (HR for combined clinical risk (CCR) = 3.86; p= 2.8x10-23).  Contrary to expectations, this large study found no evidence that AA men have more aggressive prostate cancer than non-AA men after accounting for all molecular and clinical information. “Our study confirmed that the Prolaris test significantly predicts which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach,” said Dr. Bardot.  “This study also included a large group of AA men which have historically been underrepresented in clinical outcomes studies.  This study demonstrated that Prolaris provided more accurate precision in providing prognosis in African American and non-African Americans equally.” The findings from the current study are consistent with the findings of an earlier study that demonstrated the ability of the Prolaris test in predicting cancer progression, as measured by both biochemical recurrence and metastatic disease, after radical prostatectomy. That prior study found that patients with a high Prolaris test score had a six-fold higher risk of developing metastases compared to low risk patients. Based on the strength of the data from these two outcomes studies, Myriad has added risk of metastases to the Prolaris test report for clinicians, making Prolaris the first and only genetic test to provide this endpoint as validated by two outcomes studies. “Myriad Genetics is committed to innovation and being the leader in genetic testing for men diagnosed with prostate cancer,” said Michael Brawer, M.D., senior vice president of Medical Affairs, Myriad Genetic Laboratories.  “We have multiple outcome studies that show the ability of Prolaris to predict the 10-year risk of prostate cancer specific mortality, and we now have two studies that predict the risk that treatment will fail and men will end up with metastatic disease.  We are excited to provide all of this relevant information in a single test report for clinicians.” Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #AUA17.  Details of the presentation at AUA follow. Featured Presentation Title: Evaluating the Prognostic Utility of the CCP Score for Predicting Prostate Cancer Aggressiveness in African American Men Presenter: Steven Bardot, M.D., Ochsner Medical Center Date: Saturday, May 13, 2017: 7:00-9:00 a.m. ET. Location: Moderated Poster MP28-19; Room 253AB. About Prolaris® Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease-specific mortality in patients with prostate cancer. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth.  Low gene expression is associated with a low risk of disease-specific mortality in men who may be candidates for active surveillance and high gene expression is associated with a higher risk of disease-specific mortality in patients who may benefit from additional therapy.  For more information visit: www.prolaris.com. About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Safe Harbor Statement        This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Prolaris data being presented at the at the American Urological Association’s 2017 Annual Meeting being held May 12-16, 2017 in Boston, Mass.; the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer; the ability of the Prolaris test to significantly predict which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach; and the Company's strategic directives under the caption "About Myriad Genetics."  These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.


SALT LAKE CITY, May 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new data demonstrating the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer. The data are being presented tomorrow at the American Urological Association (AUA) 2017 Annual Meeting in Boston, Mass. This study was conducted in collaboration with Stephen Bardot, M.D., and colleagues at Ochsner Clinic in New Orleans, Louisiana.  A total of 767 men with localized prostate cancer were evaluated using the Prolaris test plus CAPRA (i.e., clinical features) to predict the risk of metastatic disease up to 10 years following diagnosis.  Approximately 40 percent of the patients in the study were African Americans (AA).  Among all 767 patients 39 men, or 5.1 percent, developed metastases and among the 646 men who received definitive therapy (e.g., surgery, radiation, radiation and hormones) 28 men, or 4.3 percent, developed metastatic disease. The results showed that the Prolaris test was a significant predictor of metastatic disease with a nearly 3-fold increased risk for each one-unit increase on the Prolaris test score (Hazard Ratio per unit score = 2.76; P = 2.8x10-11).  Importantly, there was no difference in predictive performance between races (p=0.20) or treatment groups (p=0.09).  When combined with CAPRA the Prolaris test was highly predictive of metastatic disease (HR for combined clinical risk (CCR) = 3.86; p= 2.8x10-23).  Contrary to expectations, this large study found no evidence that AA men have more aggressive prostate cancer than non-AA men after accounting for all molecular and clinical information. “Our study confirmed that the Prolaris test significantly predicts which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach,” said Dr. Bardot.  “This study also included a large group of AA men which have historically been underrepresented in clinical outcomes studies.  This study demonstrated that Prolaris provided more accurate precision in providing prognosis in African American and non-African Americans equally.” The findings from the current study are consistent with the findings of an earlier study that demonstrated the ability of the Prolaris test in predicting cancer progression, as measured by both biochemical recurrence and metastatic disease, after radical prostatectomy. That prior study found that patients with a high Prolaris test score had a six-fold higher risk of developing metastases compared to low risk patients. Based on the strength of the data from these two outcomes studies, Myriad has added risk of metastases to the Prolaris test report for clinicians, making Prolaris the first and only genetic test to provide this endpoint as validated by two outcomes studies. “Myriad Genetics is committed to innovation and being the leader in genetic testing for men diagnosed with prostate cancer,” said Michael Brawer, M.D., senior vice president of Medical Affairs, Myriad Genetic Laboratories.  “We have multiple outcome studies that show the ability of Prolaris to predict the 10-year risk of prostate cancer specific mortality, and we now have two studies that predict the risk that treatment will fail and men will end up with metastatic disease.  We are excited to provide all of this relevant information in a single test report for clinicians.” Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #AUA17.  Details of the presentation at AUA follow. Featured Presentation Title: Evaluating the Prognostic Utility of the CCP Score for Predicting Prostate Cancer Aggressiveness in African American Men Presenter: Steven Bardot, M.D., Ochsner Medical Center Date: Saturday, May 13, 2017: 7:00-9:00 a.m. ET. Location: Moderated Poster MP28-19; Room 253AB. About Prolaris® Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease-specific mortality in patients with prostate cancer. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth.  Low gene expression is associated with a low risk of disease-specific mortality in men who may be candidates for active surveillance and high gene expression is associated with a higher risk of disease-specific mortality in patients who may benefit from additional therapy.  For more information visit: www.prolaris.com. About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Safe Harbor Statement        This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Prolaris data being presented at the at the American Urological Association’s 2017 Annual Meeting being held May 12-16, 2017 in Boston, Mass.; the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer; the ability of the Prolaris test to significantly predict which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach; and the Company's strategic directives under the caption "About Myriad Genetics."  These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.


SALT LAKE CITY, May 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new data demonstrating the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer. The data are being presented tomorrow at the American Urological Association (AUA) 2017 Annual Meeting in Boston, Mass. This study was conducted in collaboration with Stephen Bardot, M.D., and colleagues at Ochsner Clinic in New Orleans, Louisiana.  A total of 767 men with localized prostate cancer were evaluated using the Prolaris test plus CAPRA (i.e., clinical features) to predict the risk of metastatic disease up to 10 years following diagnosis.  Approximately 40 percent of the patients in the study were African Americans (AA).  Among all 767 patients 39 men, or 5.1 percent, developed metastases and among the 646 men who received definitive therapy (e.g., surgery, radiation, radiation and hormones) 28 men, or 4.3 percent, developed metastatic disease. The results showed that the Prolaris test was a significant predictor of metastatic disease with a nearly 3-fold increased risk for each one-unit increase on the Prolaris test score (Hazard Ratio per unit score = 2.76; P = 2.8x10-11).  Importantly, there was no difference in predictive performance between races (p=0.20) or treatment groups (p=0.09).  When combined with CAPRA the Prolaris test was highly predictive of metastatic disease (HR for combined clinical risk (CCR) = 3.86; p= 2.8x10-23).  Contrary to expectations, this large study found no evidence that AA men have more aggressive prostate cancer than non-AA men after accounting for all molecular and clinical information. “Our study confirmed that the Prolaris test significantly predicts which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach,” said Dr. Bardot.  “This study also included a large group of AA men which have historically been underrepresented in clinical outcomes studies.  This study demonstrated that Prolaris provided more accurate precision in providing prognosis in African American and non-African Americans equally.” The findings from the current study are consistent with the findings of an earlier study that demonstrated the ability of the Prolaris test in predicting cancer progression, as measured by both biochemical recurrence and metastatic disease, after radical prostatectomy. That prior study found that patients with a high Prolaris test score had a six-fold higher risk of developing metastases compared to low risk patients. Based on the strength of the data from these two outcomes studies, Myriad has added risk of metastases to the Prolaris test report for clinicians, making Prolaris the first and only genetic test to provide this endpoint as validated by two outcomes studies. “Myriad Genetics is committed to innovation and being the leader in genetic testing for men diagnosed with prostate cancer,” said Michael Brawer, M.D., senior vice president of Medical Affairs, Myriad Genetic Laboratories.  “We have multiple outcome studies that show the ability of Prolaris to predict the 10-year risk of prostate cancer specific mortality, and we now have two studies that predict the risk that treatment will fail and men will end up with metastatic disease.  We are excited to provide all of this relevant information in a single test report for clinicians.” Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #AUA17.  Details of the presentation at AUA follow. Featured Presentation Title: Evaluating the Prognostic Utility of the CCP Score for Predicting Prostate Cancer Aggressiveness in African American Men Presenter: Steven Bardot, M.D., Ochsner Medical Center Date: Saturday, May 13, 2017: 7:00-9:00 a.m. ET. Location: Moderated Poster MP28-19; Room 253AB. About Prolaris® Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease-specific mortality in patients with prostate cancer. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth.  Low gene expression is associated with a low risk of disease-specific mortality in men who may be candidates for active surveillance and high gene expression is associated with a higher risk of disease-specific mortality in patients who may benefit from additional therapy.  For more information visit: www.prolaris.com. About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Safe Harbor Statement        This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Prolaris data being presented at the at the American Urological Association’s 2017 Annual Meeting being held May 12-16, 2017 in Boston, Mass.; the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer; the ability of the Prolaris test to significantly predict which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach; and the Company's strategic directives under the caption "About Myriad Genetics."  These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.


SALT LAKE CITY, May 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new data demonstrating the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer. The data are being presented tomorrow at the American Urological Association (AUA) 2017 Annual Meeting in Boston, Mass. This study was conducted in collaboration with Stephen Bardot, M.D., and colleagues at Ochsner Clinic in New Orleans, Louisiana.  A total of 767 men with localized prostate cancer were evaluated using the Prolaris test plus CAPRA (i.e., clinical features) to predict the risk of metastatic disease up to 10 years following diagnosis.  Approximately 40 percent of the patients in the study were African Americans (AA).  Among all 767 patients 39 men, or 5.1 percent, developed metastases and among the 646 men who received definitive therapy (e.g., surgery, radiation, radiation and hormones) 28 men, or 4.3 percent, developed metastatic disease. The results showed that the Prolaris test was a significant predictor of metastatic disease with a nearly 3-fold increased risk for each one-unit increase on the Prolaris test score (Hazard Ratio per unit score = 2.76; P = 2.8x10-11).  Importantly, there was no difference in predictive performance between races (p=0.20) or treatment groups (p=0.09).  When combined with CAPRA the Prolaris test was highly predictive of metastatic disease (HR for combined clinical risk (CCR) = 3.86; p= 2.8x10-23).  Contrary to expectations, this large study found no evidence that AA men have more aggressive prostate cancer than non-AA men after accounting for all molecular and clinical information. “Our study confirmed that the Prolaris test significantly predicts which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach,” said Dr. Bardot.  “This study also included a large group of AA men which have historically been underrepresented in clinical outcomes studies.  This study demonstrated that Prolaris provided more accurate precision in providing prognosis in African American and non-African Americans equally.” The findings from the current study are consistent with the findings of an earlier study that demonstrated the ability of the Prolaris test in predicting cancer progression, as measured by both biochemical recurrence and metastatic disease, after radical prostatectomy. That prior study found that patients with a high Prolaris test score had a six-fold higher risk of developing metastases compared to low risk patients. Based on the strength of the data from these two outcomes studies, Myriad has added risk of metastases to the Prolaris test report for clinicians, making Prolaris the first and only genetic test to provide this endpoint as validated by two outcomes studies. “Myriad Genetics is committed to innovation and being the leader in genetic testing for men diagnosed with prostate cancer,” said Michael Brawer, M.D., senior vice president of Medical Affairs, Myriad Genetic Laboratories.  “We have multiple outcome studies that show the ability of Prolaris to predict the 10-year risk of prostate cancer specific mortality, and we now have two studies that predict the risk that treatment will fail and men will end up with metastatic disease.  We are excited to provide all of this relevant information in a single test report for clinicians.” Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #AUA17.  Details of the presentation at AUA follow. Featured Presentation Title: Evaluating the Prognostic Utility of the CCP Score for Predicting Prostate Cancer Aggressiveness in African American Men Presenter: Steven Bardot, M.D., Ochsner Medical Center Date: Saturday, May 13, 2017: 7:00-9:00 a.m. ET. Location: Moderated Poster MP28-19; Room 253AB. About Prolaris® Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease-specific mortality in patients with prostate cancer. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth.  Low gene expression is associated with a low risk of disease-specific mortality in men who may be candidates for active surveillance and high gene expression is associated with a higher risk of disease-specific mortality in patients who may benefit from additional therapy.  For more information visit: www.prolaris.com. About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Safe Harbor Statement        This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Prolaris data being presented at the at the American Urological Association’s 2017 Annual Meeting being held May 12-16, 2017 in Boston, Mass.; the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer; the ability of the Prolaris test to significantly predict which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach; and the Company's strategic directives under the caption "About Myriad Genetics."  These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.


SALT LAKE CITY, May 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new data demonstrating the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer. The data are being presented tomorrow at the American Urological Association (AUA) 2017 Annual Meeting in Boston, Mass. This study was conducted in collaboration with Stephen Bardot, M.D., and colleagues at Ochsner Clinic in New Orleans, Louisiana.  A total of 767 men with localized prostate cancer were evaluated using the Prolaris test plus CAPRA (i.e., clinical features) to predict the risk of metastatic disease up to 10 years following diagnosis.  Approximately 40 percent of the patients in the study were African Americans (AA).  Among all 767 patients 39 men, or 5.1 percent, developed metastases and among the 646 men who received definitive therapy (e.g., surgery, radiation, radiation and hormones) 28 men, or 4.3 percent, developed metastatic disease. The results showed that the Prolaris test was a significant predictor of metastatic disease with a nearly 3-fold increased risk for each one-unit increase on the Prolaris test score (Hazard Ratio per unit score = 2.76; P = 2.8x10-11).  Importantly, there was no difference in predictive performance between races (p=0.20) or treatment groups (p=0.09).  When combined with CAPRA the Prolaris test was highly predictive of metastatic disease (HR for combined clinical risk (CCR) = 3.86; p= 2.8x10-23).  Contrary to expectations, this large study found no evidence that AA men have more aggressive prostate cancer than non-AA men after accounting for all molecular and clinical information. “Our study confirmed that the Prolaris test significantly predicts which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach,” said Dr. Bardot.  “This study also included a large group of AA men which have historically been underrepresented in clinical outcomes studies.  This study demonstrated that Prolaris provided more accurate precision in providing prognosis in African American and non-African Americans equally.” The findings from the current study are consistent with the findings of an earlier study that demonstrated the ability of the Prolaris test in predicting cancer progression, as measured by both biochemical recurrence and metastatic disease, after radical prostatectomy. That prior study found that patients with a high Prolaris test score had a six-fold higher risk of developing metastases compared to low risk patients. Based on the strength of the data from these two outcomes studies, Myriad has added risk of metastases to the Prolaris test report for clinicians, making Prolaris the first and only genetic test to provide this endpoint as validated by two outcomes studies. “Myriad Genetics is committed to innovation and being the leader in genetic testing for men diagnosed with prostate cancer,” said Michael Brawer, M.D., senior vice president of Medical Affairs, Myriad Genetic Laboratories.  “We have multiple outcome studies that show the ability of Prolaris to predict the 10-year risk of prostate cancer specific mortality, and we now have two studies that predict the risk that treatment will fail and men will end up with metastatic disease.  We are excited to provide all of this relevant information in a single test report for clinicians.” Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #AUA17.  Details of the presentation at AUA follow. Featured Presentation Title: Evaluating the Prognostic Utility of the CCP Score for Predicting Prostate Cancer Aggressiveness in African American Men Presenter: Steven Bardot, M.D., Ochsner Medical Center Date: Saturday, May 13, 2017: 7:00-9:00 a.m. ET. Location: Moderated Poster MP28-19; Room 253AB. About Prolaris® Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease-specific mortality in patients with prostate cancer. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth.  Low gene expression is associated with a low risk of disease-specific mortality in men who may be candidates for active surveillance and high gene expression is associated with a higher risk of disease-specific mortality in patients who may benefit from additional therapy.  For more information visit: www.prolaris.com. About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Safe Harbor Statement        This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Prolaris data being presented at the at the American Urological Association’s 2017 Annual Meeting being held May 12-16, 2017 in Boston, Mass.; the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer; the ability of the Prolaris test to significantly predict which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach; and the Company's strategic directives under the caption "About Myriad Genetics."  These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.


Bedi U.S.,Ochsner Clinic
Current Atherosclerosis Reports | Year: 2013

Atherosclerosis is a complex disease associated with aberrant lipoprotein metabolism and leukocyte infiltration into arterial tissue that leads to cardiovascular diseases. Statins have emerged as among the most effective means of reducing the risk of cardiovascular disease in both primary and secondary prevention settings. Statins are the only pharmacological agents that have been consistently shown to have antiatherosclerotic effects. Statins slow atherosclerosis progression and can even induce atherosclerosis regression. Technological advances in imaging modalities to assess atherosclerosis have made possible direct visualization of atherosclerotic plaques and estimation of plaque burden and permit the evaluation of the impact of medical therapies on the natural history of plaque progression. However, owing to several limiting factors as discussed in this review, presently atherosclerotic plaque progression cannot be used as a therapeutic goal for reduction of the risk of cardiovascular disease. In this review we discuss the evidence for the use of imaging modalities in the detection of atherosclerotic plaque regression, the effects of statins on the atherosclerotic process, and the clinical relevance of atherosclerosis regression. © 2012 Springer Science+Business Media New York.


Friedell M.L.,University of Missouri - Kansas City | Vandermeer T.J.,Guthrie Clinic | Cheatham M.L.,Orlando Regional Medical Center | Fuhrman G.M.,Ochsner Clinic | And 3 more authors.
Journal of the American College of Surgeons | Year: 2014

Background Debate exists within the surgical education community about whether 5 years is sufficient time to train a general surgeon, whether graduating chief residents are confident in their skills, why residents choose to do fellowships, and the scope of general surgery practice today. Study Design In May 2013, a 16-question online survey was sent to every general surgery program director in the United States for dissemination to each graduating chief resident (CR). Results Of the 297 surveys returned, 76% of CRs trained at university programs, 81% trained at 5-year programs, and 28% were going directly into general surgery practice. The 77% of CRs who had done >950 cases were significantly more comfortable than those who had done less (p < 0.0001). Only a few CRs were uncomfortable performing a laparoscopic colectomy (7%) or a colonoscopy (6%), and 80% were comfortable being on call at a Level I trauma center. Compared with other procedures, CRs were most uncomfortable with open common bile duct explorations (27%), pancreaticoduodenectomies (38%), hepatic lobectomies (48%), and esophagectomies (60%) (p < 0.00001). Of those going into fellowships, 67% said they truly had an interest in that specialty and only 7% said it was because they were not confident in their surgical skills. Conclusions Current graduates of general surgery residencies appear to be confident in their skills, including care of the trauma patient. Fellowships are being chosen primarily because of an interest in the subspecialty. General surgery residency no longer provides adequate training in esophageal or hepatopancreatobiliary surgery. © 2014 by the American College of Surgeons.


Continuous echo guidance may add to the safety of neonatal aortic balloon valvuloplasty-carotid access is an alternative route to aortic balloon valvuloplasty in neonates Proof of preferred procedure (surgical or catheter based), procedure setting, and access site remains elusive as the disease is infrequent and single center experience remains small. © 2015 Wiley Periodicals, Inc.


Bailey M.B.,University of Kentucky | Davenport D.L.,University of Kentucky | Vargas H.D.,Ochsner Clinic | Evers B.M.,University of Kentucky | McKenzie S.P.,University of Kentucky
Diseases of the Colon and Rectum | Year: 2014

BACKGROUND: As laparoscopic surgery is applied to colorectal surgery procedures, it becomes imperative to delineate whether there is an operative duration where benefits diminish. OBJECTIVE: The purpose of this work was to determine whether benefits of a laparoscopic right colectomy compared with an open right colectomy are diminished by prolonged operative times. DESIGN: We performed a retrospective analysis comparing outcomes of patients undergoing laparoscopic right and open right colectomy for colon cancer with operative duration of less than and greater than 3 hours. SETTINGS: This study was based on data in the American College of Surgeons National Surgical Quality Improvement Program database. PATIENTS: We queried the database for patients with laparoscopic and open right colectomy with a diagnosis of colorectal cancer between 2005 and 2010. MAIN OUTCOME MEASURES: Patients were stratified by operative technique and duration. Forward multivariable logistic regression analysis was performed for mortality, cerebrovascular/cardiovascular complications, and infectious complications. Predictors of operative time >3 hours in the laparoscopic cohort were identified by logistic regression. RESULTS: Of 4273 patients, operative duration was > 3 hours for 18.4% of patients with a laparoscopic right colectomy and 11.3% with an open right colectomy. There was no benefit of the laparoscopic right colectomy with an operative duration >3 hours over open right colectomy with respect to mortality and cardiopulmonary and cerebrovascular complications. An operative duration >3 hours was an independent risk factor for infectious complications in patients undergoing a laparoscopic right colectomy. LIMITATIONS: This was a retrospective study and not an intention-to-treat analysis. CONCLUSIONS: At an operative duration of =3 hours, laparoscopic right colectomy has higher infectious complications than open right colectomy. Reduced mortality and less cardiopulmonary and cerebrovascular complications seen in the laparoscopic cohort with shorter operative duration were lost with an operative duration >3 hours. In patients at risk for prolonged laparoscopic right colectomy, early conversion to an open technique may be warranted. © The ASCRS 2014.


The International Association of HealthCare Professionals is pleased to welcome Thomas J. Sultenfuss, MD, to their prestigious organization with his upcoming publication in The Leading Physicians of the World. He is a highly-trained and qualified dermatologist with an extensive expertise in all facets of his work. Dr. Thomas J. Sultenfuss has been in practice for more than 39 years, and is currently serving patients within his own private practice in Dunedin, Florida. Dr. Thomas J. Sultenfuss’ career in medicine began in 1977 when he graduated with his Medical Degree from Tulane University in New Orleans, Louisiana. Following his graduation, Dr. Sultenfuss subsequently completed his internship at the Alton Ochsner Clinic in Jefferson, Louisiana which was in turn succeeded by a Dermatology residency at the University of Miami in Jackson. Dr. Sultenfuss holds board certification in Dermatology and has a clinical interest in learning new techniques and methodologies in the field of dermatology. Dr. Sultenfuss has previously taught at the University of South Florida, and is the co-author of A Woman’s Guide to Vitamins, Minerals and Alternative Healing alongside his wife Sherry Wilson Sultenfuss. Dr. Sultenfuss attributes his great success to his love for dermatology, and when he is not assisting patients, he likes to relax by woodworking. Learn more about Dr. Sultenfuss by reading his upcoming publication in The Leading Physicians of the World. FindaTopDoc.com is a hub for all things medicine, featuring detailed descriptions of medical professionals across all areas of expertise, and information on thousands of healthcare topics.  Each month, millions of patients use FindaTopDoc to find a doctor nearby and instantly book an appointment online or create a review.  FindaTopDoc.com features each doctor’s full professional biography highlighting their achievements, experience, patient reviews and areas of expertise.  A leading provider of valuable health information that helps empower patient and doctor alike, FindaTopDoc enables readers to live a happier and healthier life.  For more information about FindaTopDoc, visit http://www.findatopdoc.com

Loading Ochsner Clinic collaborators
Loading Ochsner Clinic collaborators